NEW YORK (GenomeWeb News) – Quest Diagnostics this week announced a definitive agreement to buy full-service commercial laboratory firm Solstas Lab Partners for $570 million. Quest is buying Solstas from private equity firm Welsh, Carson, Anderson, and Stowe. Based in Greensboro, NC, Solstas operates in nine states in the Southeastern US. Quest said the deal is anticipated to add about 5 percent in annualized revenues and to be "modestly" accretive to adjusted EPS in 2014. The deal is expected to be completed in the first half of the year.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has approved Kite Pharmaceuticals' CAR T-cell therapy for large B-cell lymphomas, the New York Times reports.

Kaiser Health News reports that gene therapies could cost more than a million dollars.

Worcester Polytechnic Institute researchers have received a grant to combine biology and computer science for high school students.

In Nature this week: variants associated with obsessive-compulsive disorder, review of key CRISPR enzymes, and more.